Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

13.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.2K
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HAC1 contributes to stress adaptation and virulence in the emerging fungal pathogen Candida auris.

Medical mycology·2026
Same author

Influence of hypoxic conditions on Trichosporon asahii virulence in a Galleria mellonella infection model.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2026
Same author

Clinical and Microbiological Insights Into Invasive Fusariosis Following Allogeneic Hematopoietic Stem Cell Transplantation: A 15-Year Single-Center Analysis.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same author

Comparative Evaluation of 3D-QALAS Myelin Volume Fraction, Inhomogeneous Magnetization Transfer, and Myelin Water Fraction.

AJNR. American journal of neuroradiology·2026
Same author

Post-radiofrequency ablation empyema-a staged multidisciplinary protocol for colonic and diaphragmatic perforation: a case report.

AME case reports·2026
Same author

A modified Cerfolio technique for robotic pulmonary resection: a retrospective comparison with the conventional approach.

General thoracic and cardiovascular surgery·2026
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Related Experiment Video

Updated: May 5, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K

[Multiple myeloma].

Masahiro Abe1

  • 1Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 13, 2009
PubMed
Summary
This summary is machine-generated.

Multiple myeloma bone disease management involves bisphosphonates and bortezomib. Understanding their long-term effects and risks, like osteonecrosis of the jaw, is crucial for effective treatment.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

5.7K

Related Experiment Videos

Last Updated: May 5, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

5.7K

Area of Science:

  • Oncology
  • Bone Biology
  • Pharmacology

Context:

  • Multiple myeloma frequently leads to severe bone complications such as pain, fractures, and hypercalcemia.
  • Bisphosphonates are standard treatments for preventing skeletal-related events in myeloma patients.
  • Long-term bisphosphonate efficacy and safety, particularly concerning osteonecrosis of the jaw (ONJ), require further investigation.

Purpose:

  • To evaluate the roles of bone-targeting agents in managing myeloma bone disease.
  • To clarify the benefits and risks associated with bisphosphonates and proteasome inhibitors like bortezomib.
  • To optimize the use of these agents by mitigating adverse effects.

Summary:

  • Bisphosphonates inhibit osteoclast activity, reducing bone destruction in multiple myeloma.
  • The proteasome inhibitor bortezomib shows potential anabolic effects, promoting bone formation.
  • Concerns exist regarding long-term bisphosphonate use, specifically the risk of osteonecrosis of the jaw.

Impact:

  • Improved understanding of bone-targeting therapies for multiple myeloma.
  • Guidance on balancing the benefits of bisphosphonates and bortezomib against potential side effects.
  • Potential for enhanced treatment strategies to preserve bone health in myeloma patients.